

Filgrastim: Nypozi® brand switch – Information for Patients

What is the situation?

Starting May 1st, 2025 BC Cancer will start using Nypozi® as the filgrastim brand, instead of other filgrastim biosimilars, Grastofil® and Nivestym®.

What will change for me?

Your filgrastim prescription may now be filled with the Nypozi® brand instead of the previous filgrastim biosimilar brand (Grastofil®).

Key Information:

- Filgrastim is a drug that helps your bone marrow make new white blood cells. White blood cells protect your body by fighting bacteria (germs) that cause infection. Filgrastim is a clear liquid that is injected under your skin or into a vein.
- Your total daily dose of filgrastim stays the same. You should expect to have the same results and the same side effects.
- A biosimilar is a biologic medicine (a medicine made inside of a living cell) that works the same as the original brand name biologic drug (reference biologic).
- Biosimilars are as safe and effective (work just as well) as the reference biologic drug and work the same way as the reference biologic drug.
- Health Canada has strict rules that companies must follow when making and testing a biosimilar. All biosimilars used in Canada must meet the same high standards as reference biologics. Additional information can be found at BC Cancer's biosimilars website: bccancer.bc.ca/biosimilars

Please follow the instructions from your healthcare provider on how and when to take medication.

Where can I get more information?

Please talk to your cancer oncologist, pharmacist, or nurse if you have questions.

BC Cancer – Abbotsford: 604-851-4710

BC Cancer – Surrey: 604-930-2098

BC Cancer – Kelowna: 250-712-3900

BC Cancer – Vancouver: 604-877-6000

BC Cancer – Prince George: 250-645-7300

BC Cancer – Victoria: 250-519-5500